Hypogonadism and Mortality in Aged Hospitalized Male Patients: A 5-Year Prospective Observational Study

 

 Buy Article Permissions and Reprints

Abstract

Objective: To investigate the relationship between hypogonadism and mortality in aged hospitalized male patients.

Design: A 5-year prospective observational study was conducted. Gonadal function was assessed at hospital admission and mortality was registered in the follow-up period.

Patients and Methods: We studied all patients≥65 years admitted for any reason during 2010 and 2011. Serum T concentrations were quantified in all patients. Hypogonadism was defined by the presence of serum T levels<200 ng/dl. Number of deaths and all-cause and cardiovascular (CV) mortality were registered until December 31^st, 2014.

Results: During the study 150 patients were admitted and 103 (68.7%) of them died during follow-up. Hypogonadism was positively associated with mortality (P=0.036). The percentage of hypogonadal patients was significantly (P=0.02) higher in the group of patients who died in hospital compared with those who died after hospital discharge and those who survived. CV disease was the main cause of death in 52 patients (50.5%). Kaplan-Meier analysis showed a median survival time for all-cause mortality of 2.0 (0–16.5) months and 21.0 (5.0–33.2) months for patients with and without hypogonadism, respectively (P<0.001). Similar findings were found when analyzing mortality due to CV disease (P=0.009). Hypogonadism was a strong independent predictor for all-cause (adjusted multivariate analysis, HR 3.35; 1.55–7.23, P=0.002) and CV mortality (HR 2.14; 1.18–3.86, P=0.012).

Conclusions: Hypogonadism discovered during hospitalization is associated with in-hospital and long-term mortality in elderly male patients and predicts both all-cause mortality and CV mortality in this population.

• References

• 1 Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507-514
  CrossrefPubMedGoogle Scholar
• 2 Venkat K, Desai M, Arora MM et al. Age-related changes in sex steroid levels influence bone mineral density in healthy indian men. Osteoporos Int 2009; 20: 955-962
  CrossrefPubMedGoogle Scholar
• 3 Saad F, Gooren LJ. Late onset hypogonadism of men is not equivalent to the menopause. Maturitas 2014; 79: 52-57
  CrossrefPubMedGoogle Scholar
• 4 Araujo AB, Esche GR, Kupelian V et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-4247
  CrossrefPubMedGoogle Scholar
• 5 Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009; 30: 1-9
  PubMedGoogle Scholar
• 6 Tajar A, Huhtaniemi IT, O’Neill TW et al. Characteristics of androgen deficiency in late-onset hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97: 1508-1516
  CrossrefPubMedGoogle Scholar
• 7 Cauley JA, Ewing SK, Taylor BC et al. Sex steroid hormones in older men: Longitudinal associations with 4.5-year change in hip bone mineral density – the osteoporotic fractures in men study. J Clin Endocrinol Metab 2010; 95: 4314-4323
  CrossrefPubMedGoogle Scholar
• 8 Camacho EM, Huhtaniemi IT, O'Neill TW et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: Longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445-455
  CrossrefPubMedGoogle Scholar
• 9 Araujo AB, Dixon JM, Suarez EA et al. Clinical review: Endogenous testosterone and mortality in men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-3019
  CrossrefPubMedGoogle Scholar
• 10 Pye SR, Huhtaniemi IT, Finn JD et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab 2014; 99: 1357-1366
  CrossrefPubMedGoogle Scholar
• 11 Iglesias P, Prado F, Macias MC et al. Hypogonadism in aged hospitalized male patients: Prevalence and clinical outcome. J Endocrinol Invest 2014; 37: 135-141
  CrossrefPubMedGoogle Scholar
• 12 Iglesias P, Prado F, Munoz A et al. Natural course of hypogonadism diagnosed during hospitalization in aged male patients. Endocrine 2015; 48: 978-984
  CrossrefPubMedGoogle Scholar
• 13 Harman SM, Metter EJ, Tobin JD et al. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731
  CrossrefPubMedGoogle Scholar
• 14 Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male 2002; 5: 170-176
  CrossrefPubMedGoogle Scholar
• 15 Araujo AB, O’Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-5926
  CrossrefPubMedGoogle Scholar
• 16 Yeap BB, Hyde Z, Almeida OP et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94: 2353-2359
  CrossrefPubMedGoogle Scholar
• 17 Hyde Z, Norman PE, Flicker L et al. Elevated LH predicts ischaemic heart disease events in older men: The Health in Men Study. Eur J Endocrinol 2011; 164: 569-577
  CrossrefPubMedGoogle Scholar
• 18 Rastrelli G, Corona G, Lotti F et al Relationship of testis size and LH levels with incidence of major adverse cardiovascular events in older men with sexual dysfunction. J Sex Med 2013; 10: 2761-2773
  CrossrefPubMedGoogle Scholar
• 19 Haring R, Teng Z, Xanthakis V et al RS. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol (Oxf) 2013; 78: 629-634
  CrossrefPubMedGoogle Scholar
• 20 Khaw KT, Dowsett M, Folkerd E et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701
  CrossrefPubMedGoogle Scholar
• 21 Haring R, Volzke H, Steveling A et al Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J 2010; 31: 1494-1501
  CrossrefPubMedGoogle Scholar
• 22 Smith GD, Ben-Shlomo Y, Beswick A et al. Cortisol, testosterone, and coronary heart disease: Prospective evidence from the Caerphilly study. Circulation 2005; 112: 332-340
  CrossrefPubMedGoogle Scholar
• 23 Araujo AB, Kupelian V, Page ST et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007; 167: 252-1260
  PubMedGoogle Scholar
• 24 Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75
  CrossrefPubMedGoogle Scholar
• 25 Tivesten A, Vandenput L, Labrie F et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94: 2482-2488
  CrossrefPubMedGoogle Scholar
• 26 Haring R, Teng Z, Xanthakis V et al Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol (Oxf) 2013; 78: 629-634
  CrossrefPubMedGoogle Scholar
• 27 Hyde Z, Norman PE, Flicker L et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: The Health in Men Study. J Clin Endocrinol Metab 2012; 97: 179-189
  CrossrefPubMedGoogle Scholar